{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:43:24Z","timestamp":1778546604227,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aim<\/jats:title><jats:p>To describe the utilization of the first antiepileptic drug (AED) in men and women with previous stroke in a nationwide population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prescription data, patient's age, and sex were collected from the Swedish Drug Register and cross\u2010linked to diagnosis data from the National Patient Register and data from Statistics Sweden. Patients with a first dispensation of an AED after stroke between 1 January 2007 and 31 December 2014 were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 10\u00a0958 patients with stroke were initiated on AED treatment (51% women, mean age 75\u2009years). Gabapentin (n\u00a0=\u00a03073, 28%), pregabalin (n\u00a0=\u00a02476, 22%), carbamazepine (n\u00a0=\u00a02330, 21%), levetiracetam (n\u00a0=\u00a01158, 10%), and valproic acid (n\u00a0=\u00a0833, 7%) were the most dispensed AEDs. After stratification by the presence of a neuropathic pain diagnosis, gabapentin, and pregabalin were the most used AEDs. In contrast, after stratification for epilepsy\/convulsions diagnosis, carbamazepine and levetiracetam were the most initiated AEDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study suggests that AED is mainly used for neuropathic\/poststroke pain and the study shows gabapentin and pregabalin to be the most used AEDs. For epilepsy, carbamazepine and levetiracetam were the most used AEDs in patients with previous stroke.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hsr2.405","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T22:40:59Z","timestamp":1633128059000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antiepileptic medicines in men and women with stroke in Sweden, a registry\u2010based study"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-7783","authenticated-orcid":false,"given":"Linn\u00e9a","family":"Karlsson Lind","sequence":"first","affiliation":[{"name":"Health and Medical Care Administration Region Stockholm  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3845-8100","authenticated-orcid":false,"given":"Mia","family":"von Euler","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Medical Sciences, School of Medicine \u00d6rebro University  \u00d6rebro Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00992.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.09.030"},{"key":"e_1_2_10_4_1","first-page":"33","article-title":"Poststroke epilepsy: update on diagnosis, treatment and prognosis","volume":"114","author":"Zelano J","year":"2017","journal-title":"Lakartidningen"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.08.001"},{"key":"e_1_2_10_6_1","unstructured":"Swedish Medical Products Agency (MPA). Medical treatment of epilepsy \u2010 treatment recommendation (in Swedish).https:\/\/www.lakemedelsverket.se\/48d853\/globalassets\/dokument\/behandling-och-forskrivning\/behandlingsrekommendationer\/behandlingsrekommendation\/behandlingsrekommendation-epilepsi.pdf. 2019. Accessed February 26 2020."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2396987317705536"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.010259"},{"key":"e_1_2_10_9_1","first-page":"CD006044","article-title":"Lamotrigine for chronic neuropathic pain and fibromyalgia in adults","volume":"12","author":"Wiffen PJ","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2019.08.014"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318254"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12536"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_2_10_17_1","unstructured":"Statistics Sweden. Statistics Sweden (SCB); 1997.https:\/\/www.scb.se\/."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"e_1_2_10_19_1","first-page":"CD007076","article-title":"Pregabalin for neuropathic pain in adults","volume":"1","author":"Derry S","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_20_1","first-page":"CD005612","article-title":"Pregabalin add\u2010on for drug\u2010resistant focal epilepsy","volume":"7","author":"Panebianco M","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_21_1","unstructured":"European Medicines Agency (EMA). Lyrica (pregabalin). EPAR \u2010 Product information.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lyrica-epar-product-information_en.pdf. Accessed February 26 2020."},{"key":"e_1_2_10_22_1","unstructured":"European Medicines Agency (EMA). Neurontin (gabapentin).https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/neurontin. Accessed February 26 2020."},{"key":"e_1_2_10_23_1","unstructured":"Tegretol (carbamazepine).Summary of Product Characteristics . Swedish Medical Products Agency. Updated January 23 2019. Cited February 26 2020."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13025"},{"key":"e_1_2_10_25_1","first-page":"CD010943","article-title":"Levetiracetam for neuropathic pain in adults","volume":"7","author":"Wiffen PJ","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.09.003"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922007949"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.11.013"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000110933"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345953"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004094"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.405","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:48:27Z","timestamp":1692989307000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/hsr2.405"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.405","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"2021-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e405"}}